JP2021534815A5 - - Google Patents

Info

Publication number
JP2021534815A5
JP2021534815A5 JP2021531201A JP2021531201A JP2021534815A5 JP 2021534815 A5 JP2021534815 A5 JP 2021534815A5 JP 2021531201 A JP2021531201 A JP 2021531201A JP 2021531201 A JP2021531201 A JP 2021531201A JP 2021534815 A5 JP2021534815 A5 JP 2021534815A5
Authority
JP
Japan
Prior art keywords
domain
human
car according
cells
intracellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021531201A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534815A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/000907 external-priority patent/WO2020030979A2/en
Publication of JP2021534815A publication Critical patent/JP2021534815A/ja
Publication of JP2021534815A5 publication Critical patent/JP2021534815A5/ja
Priority to JP2024099001A priority Critical patent/JP2024123133A/ja
Pending legal-status Critical Current

Links

JP2021531201A 2018-08-10 2019-08-09 Ｔｎｆｒ２ドメインを含む新規ｃａｒ構築物 Pending JP2021534815A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024099001A JP2024123133A (ja) 2018-08-10 2024-06-19 Ｔｎｆｒ２ドメインを含む新規ｃａｒ構築物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862717234P 2018-08-10 2018-08-10
US62/717,234 2018-08-10
PCT/IB2019/000907 WO2020030979A2 (en) 2018-08-10 2019-08-09 New car constructs comprising tnfr2 domains

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024099001A Division JP2024123133A (ja) 2018-08-10 2024-06-19 Ｔｎｆｒ２ドメインを含む新規ｃａｒ構築物

Publications (2)

Publication Number Publication Date
JP2021534815A JP2021534815A (ja) 2021-12-16
JP2021534815A5 true JP2021534815A5 (enExample) 2022-08-17

Family

ID=68470557

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021531201A Pending JP2021534815A (ja) 2018-08-10 2019-08-09 Ｔｎｆｒ２ドメインを含む新規ｃａｒ構築物
JP2024099001A Pending JP2024123133A (ja) 2018-08-10 2024-06-19 Ｔｎｆｒ２ドメインを含む新規ｃａｒ構築物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024099001A Pending JP2024123133A (ja) 2018-08-10 2024-06-19 Ｔｎｆｒ２ドメインを含む新規ｃａｒ構築物

Country Status (12)

Country Link
US (1) US20210292389A1 (enExample)
EP (1) EP3833446A2 (enExample)
JP (2) JP2021534815A (enExample)
KR (1) KR20210046006A (enExample)
CN (1) CN112888481A (enExample)
AU (1) AU2019318135A1 (enExample)
BR (1) BR112021002579A2 (enExample)
CA (1) CA3109253A1 (enExample)
IL (1) IL280697A (enExample)
MX (1) MX2021001592A (enExample)
SG (1) SG11202101415UA (enExample)
WO (1) WO2020030979A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
EP3808766A1 (en) * 2019-10-15 2021-04-21 Sangamo Therapeutics France Chimeric antigen receptor specific for interleukin-23 receptor
US20230121433A1 (en) * 2020-03-11 2023-04-20 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
CN113528449A (zh) * 2020-04-20 2021-10-22 浙江瑞加美生物科技有限公司 一种制备通用型人源化car19-dnt细胞的技术及其应用
BR112023014615A2 (pt) * 2021-01-20 2023-10-03 Seoul Nat Univ Hospital Células t reguladoras de receptor de antígeno quimérico anti-c4d e usos das mesmas.
JP2024526201A (ja) * 2021-06-25 2024-07-17 サンガモ セラピューティクス，インコーポレイテッド Ｉｌ－２３ｒに特異的な抗原結合体及びその使用
WO2023010122A2 (en) * 2021-07-29 2023-02-02 Sonoma Biotherapeutics, Inc. Synovial extracellular matrix-specific chimeric antigen receptor for targeting regulatory t cells to treat autoimmune diseases
WO2023076912A2 (en) * 2021-10-26 2023-05-04 ImmPACT Bio USA Inc. Cd4+ and/or cd8+ cell populations comprising icars for use in treatment therapies
CN114262689A (zh) * 2021-12-17 2022-04-01 上海纳米技术及应用国家工程研究中心有限公司 一种快速检测cd19/cd20-car-t细胞活性的方法
WO2023156587A1 (en) * 2022-02-18 2023-08-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tcr-deficient car-tregs in combination with anti-tcr complex monoclonal antibodies for inducing durable tolerance
WO2025006795A1 (en) * 2023-06-30 2025-01-02 Board Of Regents, The University Of Texas System Tsyn-seq: a t cell synapse-based tumor antigen identification platform
WO2025170881A1 (en) * 2024-02-06 2025-08-14 The Board Of Trustees Of The University Of Illinois Methods and kits for reducing the risk of allograft rejection
WO2025250847A1 (en) * 2024-05-29 2025-12-04 The Texas A&M University System Compositions containing hsp60-specific regulatory t cells and methods of treatment using the same

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
WO2004094642A2 (en) 2003-04-24 2004-11-04 Fondazione Centro San Raffaele Del Monte Tabor Lentiviral vectors carrying synthetic bi-directional promoters and uses thereof
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
US20070036773A1 (en) 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
GB0603081D0 (en) 2006-02-15 2006-03-29 Dynal Biotech Asa Oslo Method
PT2126054T (pt) 2007-01-31 2016-10-12 Yeda Res & Dev Células t reguladoras geneticamente modificadas, redirecionadas e sua utilização na supressão de doenças inflamatórias e autoimunitárias
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
CA2805442C (en) 2010-07-21 2020-05-12 Sangamo Biosciences, Inc. Methods and compositions for modification of an hla locus
EP3459560B1 (en) 2011-04-08 2021-02-24 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
CN105209621B (zh) 2012-12-12 2021-05-25 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
KR102955556B1 (ko) 2012-12-12 2026-04-22 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
ES2918501T3 (es) * 2013-12-19 2022-07-18 Novartis Ag Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
WO2015090229A1 (en) * 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
WO2015142661A1 (en) * 2014-03-15 2015-09-24 Novartis Ag Regulatable chimeric antigen receptor
CN122399016A (zh) * 2014-03-15 2026-07-17 诺华股份有限公司 使用嵌合抗原受体治疗癌症
EP3180359A1 (en) * 2014-08-14 2017-06-21 Novartis AG Treatment of cancer using gfr alpha-4 chimeric antigen receptor
WO2016184570A1 (en) 2015-05-18 2016-11-24 Numab Ag Novel treatment methods based on multifunctional molecules
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
SG10201912519VA (en) * 2016-04-01 2020-02-27 Kite Pharma Inc Chimeric receptors and methods of use thereof
CN109983027A (zh) * 2016-10-20 2019-07-05 细胞基因公司 基于cereblon的可异二聚化嵌合抗原受体
US11286306B2 (en) * 2016-12-09 2022-03-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. TLR9-binding chimeric antigen receptors
CN108276493B (zh) * 2016-12-30 2023-11-14 南京传奇生物科技有限公司 一种嵌合抗原受体及其应用
CN110678190A (zh) 2017-03-28 2020-01-10 宾夕法尼亚大学董事会 保护移植的组织免受排斥的方法
KR102742220B1 (ko) 2017-09-19 2024-12-17 더 유니버시티 오브 브리티쉬 콜롬비아 항-hla-a2 항체 및 그 사용 방법

Similar Documents

Publication Publication Date Title
JP6574848B2 (ja) Ｃｄ１９結合ドメインを含むキメラ抗原レセプター（ｃａｒ）
JP6936497B2 (ja) 多価Ｆｖ抗体
EP3114147B1 (en) Chimeric antigen receptor
JP2021177771A5 (enExample)
JP2023527049A5 (enExample)
US20210177951A1 (en) Engineered cells & methods
JP2018521663A5 (enExample)
JP2016520074A5 (enExample)
WO2020017479A1 (ja) 抗ｇｐｃ３一本鎖抗体を含むｃａｒ
JP2022505445A5 (enExample)
JP2021511041A5 (enExample)
CN112739721A (zh) 一种单域抗体及包含抗体结构的嵌合抗原受体
JP2007530435A5 (enExample)
JP2016538855A5 (enExample)
JP2017500869A5 (enExample)
WO2023193662A1 (zh) 靶向bcma的嵌合抗原受体及其应用
JP2021525534A5 (enExample)
JP2023518538A5 (enExample)
CN105384825A (zh) 一种基于单域抗体的双特异性嵌合抗原受体及其应用
JP2021506275A5 (enExample)
JP2024507540A5 (enExample)
CN114249832B (zh) 一种靶向cpsg4的人源化嵌合抗原受体及表达该嵌合抗原受体的免疫效应细胞及其应用
WO2018229492A1 (en) Chimeric antigen receptor
JP2018502068A5 (enExample)
JP2026016543A5 (enExample)